

Cynata Receives Notice of Allowance received from US Patent Office for Novel MSC Manufacturing Technology

Melbourne, Australia; 11 November 2022: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has today announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for a patent application covering its proprietary Cymerus™ mesenchymal stem cell (MSC) platform technology. The patent application entitled “Pluripotent Stem Cell Assay” is wholly owned by Cynata and describes a novel method for ensuring quality and purity of Cynata’s finished therapeutic MSC products.

The Notice of Allowance is sent to the applicant when the USPTO intends to issue a patent. The patent adds to the existing broad and comprehensive IP protection of the Cymerus manufacturing platform and its unique ability to yield highly consistent MSCs at scale, from a single donation, to create therapeutic stem cell products.

Dr Kilian Kelly, Cynata’s Chief Operating Officer, said:

“We are delighted that our product development activities have resulted in yet a further patent, particularly in the USA, a key commercial jurisdiction. This important achievement adds to our portfolio of wholly-Cynata owned patents and patent applications, providing further protection over our proprietary Cymerus technology to 2037 and beyond. The novel method described in the patent specification and patent claims enhances our competitive position around the Cymerus platform which enables the production of consistent, high-quality mesenchymal stem cells at scale. These important characteristics afford a major competitive advantage in the ongoing development of off-the-shelf therapeutic stem cell products to target a range of devastating diseases worldwide”.

Cynata anticipates that the patent will be granted around February 2023, with an expiration date of 15 November 2037.

-ENDS-

Authorised for release by Dr Ross Macdonald, Managing Director & CEO

CONTACTS: Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119 343, ross.macdonald@cynata.com
Lauren Nowak, Media Contact, +61 (0)400 434 299, laurenmaree@live.com.au

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Planning for a Phase 2 clinical trial in GvHD under a cleared US FDA IND is presently underway. Clinical trials of Cymerus products in osteoarthritis (Phase 3), respiratory failure and diabetic foot ulcers (DFU) are currently ongoing. In addition, Cynata has demonstrated utility of its



Cymerus technology in preclinical models of numerous diseases, including the clinical targets mentioned above, as well as critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.